Conformational changes and cleavage; are these responsible for the tau aggregation in Alzheimer's disease?

Future Neurology

Volumn 4, Issue 1, 2009, Pages 39-53

  Mondragón Rodríguez, Siddhartha ^a   Basurto Islas, Gustavo ^a   Binder, Lester I ^b   García Sierra, Francisco ^a  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Aggregation; Alzheimer's disease; Cleavage; Conformational changes; Neurofibrillary tangles; Neuronal toxicity; Phosphorylated tau

Indexed keywords

TAU PROTEIN;

ALZHEIMER DISEASE; CONFORMATIONAL TRANSITION; CYTOTOXICITY; HUMAN; IN VITRO STUDY; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW;

EID: 67149128179     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.4.1.39     Document Type: Review

References (125)

1. Goedert M: Neurofibrillary pathology of Alzheimer's disease and other tauopathies. Prog. Brain Res. 117, 287-306 (1998).
2. Braak H, Braak E, Bohl J, Bratzke H: Evolution of Alzheimer's disease related cortical lesions. J. Neural Transm. Suppl. 54, 97-106 (1998).
3. Jellinger KA: The neuropathological diagnosis of Alzheimer disease. J. Neural Transm. Suppl. 53, 97-118 (1998).
4. Geddes JW, Tekirian TL, Soultanian NS, Ashford JW, Davis DG, Markesbery WR: Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease. Neurobiol. Aging 18, S99-S105 (1997).
5. Braak H, Braak E: Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol. Aging 18, S85-S88 (1997).
6. Duyckaerts C, Hauw JJ: Diagnosis and staging of Alzheimer disease. Neurobiol. Aging 18, S33-S42 (1997).
7. Hama E, Saido TC: Etiology of sporadic Alzheimer's disease: somatostatin, neprilysin, and amyloid β peptide. Med. Hypotheses 65, 498-500 (2005).
8. Frankish H: Unravelling the mechanism of amyloid-β toxicity in AD. Lancet Neurol. 4, 526 (2005).
9. Tanimukai H, Grundke-Iqbal I, Iqbal K: Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am. J. Pathol. 166, 1761-1771 (2005).
10. Iqbal K, Alonso Adel C, Chen S et al.: Tau pathology in Alzheimer disease and other tauopathies. Biochim. Biophys. Acta 1739, 198-210 (2005).
11. Goedert M, Klug A: Tau protein and the paired helical filament of Alzheimer's disease. Brain Res. Bull. 50, 469-470 (1999).
12. Goedert M, Jakes R, Crowther RA, Hasegawa M, Smith MJ, Spillantini MG: Intraneuronal filamentous tau protein and α-synuclein deposits in neurodegenerative diseases. Biochem. Soc. Trans. 26, 463-471 (1998).
13. Goedert M: Tau protein and the neurofibrillary pathology of Alzheimer's disease. Ann. NY Acad. Sci. 777, 121-131 (1996).
14. Carmel G, Mager EM, Binder LI, Kuret J: The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology. J. Biol. Chem. 271, 32789-32795 (1996).
15. Ghoshal N, Garcia-Sierra F, Fu Y et al.: Tau-66: evidence for a novel tau conformation in Alzheimer's disease. J. Neurochem. 77, 1372-1385 (2001).
16. Weaver CL, Espinoza M, Kress Y, Davies P: Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol. Aging 21, 719-727 (2000).
17. Gamblin TC, Chen F, Zambrano A et al.: Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl Acad. Sci. USA 100, 10032-10037 (2003).
18. Wischik CM, Novak M, Thogersen HC et al.: Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc. Natl Acad. Sci. USA 85, 4506-4510 (1988).
19. Wischik CM, Novak M, Edwards PC, Klug A, Tichelaar W, Crowther RA: Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc. Natl Acad. Sci. USA 85, 4884-4888 (1988).
20. Novak M, Jakes R, Edwards PC, Milstein C, Wischik CM: Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51. Proc. Natl Acad. Sci. USA 88, 5837-5841 (1991).
21. Rissman RA, Poon WW, Blurton-Jones M et al.: Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J. Clin. Invest. 114, 121-130 (2004).
22. Fabian H, Otvos L Jr, Szendrei GI, Lang E, Mantsch HH: Tyrosine- versus serine-phosphorylation leads to conformational changes in a synthetic tau peptide. J. Biomol. Struct. Dyn. 12, 573-579 (1994).
23. Garcia-Sierra F, Ghoshal N, Quinn B, Berry RW, Binder LI: Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease. J. Alzheimers Dis. 5, 65-77 (2003).
24. Luna-Munoz J, Chavez-Macias L, Garcia-Sierra F, Mena R: Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J. Alzheimers Dis. 12, 365-375 (2007).
25. Mondragon-Rodriguez S, Basurto-Islas G, Santa-Maria I et al.: Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease. Int. J. Exp. Path. 89(2), 81-90 (2008).
26. Garcia-Sierra F, Basurto-Islas G, Santa-Maria I, Mena R, Luna-Muñoz J, Binder LI: Tau protein expressed in COS-7 cells displays similar phosphorylation and conformational changes as it occurs in Alzheimer's disease brains. FENS Forum Abstracts 217.7, Vol 4 (2008).
27. Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR et al.: Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol. Aging 26, 1015-1022 (2005).
28. Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW: Tau, tangles, and Alzheimer's disease. Biochim. Biophys. Acta 1739, 216-223 (2005).
29. Barghorn S, Davies P, Mandelkow E: Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on β-structure in the core domain. Biochemistry 43, 1694-1703 (2004).
30. Sadqi M, Hernandez F, Pan U et al.: α-helix structure in Alzheimer's disease aggregates of tau-protein. Biochemistry 41, 7150-7155 (2002).
31. Jicha GA, Berenfeld B, Davies P: Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. J. Neurosci. Res. 55, 713-723 (1999).
32. Jicha GA, Lane E, Vincent I, Otvos L Jr, Hoffmann R, Davies P: A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J. Neurochem. 69, 2087-2095 (1997).
33. Luna-Munoz J, Garcia-Sierra F, Falcon V, Menendez I, Chavez-Macias L, Mena R: Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz-50 antibody in Alzheimer's disease. J. Alzheimers Dis. 8, 29-41 (2005).
34. Jeganathan S, Hascher A, Chinnathambi S, Biernat J, Mandelkow EM, Mandelkow E: Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of tau and generates a pathological (MC-1) conformation. J. Biol. Chem. 283(46), 32066-32076 (2008).
35. Garcia-Sierra F, Mondragon-Rodriguez S, Basurto-Islas G: Truncation of tau protein and its pathological significance in Alzheimer's disease. J. Alzheimers Dis. 14, 401-409 (2008).
36. Lee VM, Otvos L Jr, Schmidt ML, Trojanowski JQ: Alzheimer disease tangles share immunological similarities with multiphosphorylation repeats in the two large neurofilament proteins. Proc. Natl Acad. Sci. USA 85, 7384-7388 (1988).
37. Okuyama K, Nishiura C, Mizushima F et al.: Linkage-dependent contribution of repeat peptides to self-aggregation of three- or four-repeat microtubule-binding domains in tau protein. FEBS J. 275, 1529-1539 (2008).
38. -. Phys. Rev. Lett. 99(1), 011801 (2007).
39. Du JT, Yu CH, Zhou LX et al.: Phosphorylation modulates the local conformation and self-aggregation ability of a peptide from the fourth tau microtubule-binding repeat. FEBS J. 274, 5012-5020 (2007).
40. Ghoshal N, Garcia-Sierra F, Wuu J et al.: Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp. Neurol. 177, 475-493 (2002).
41. Kang HJ, Yoon WJ, Moon GJ et al.: Caspase-3-mediated cleavage of PHF-1 tau during apoptosis irrespective of excitotoxicity and oxidative stress: an implication to Alzheimer's disease. Neurobiol. Dis. 18, 450-458 (2005).
42. Rohn TT, Rissman RA, Davis MC, Kim YE, Cotman CW, Head E: Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol. Dis. 11, 341-354 (2002).
43. Novak M, Kabat J, Wischik CM: Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J. 12, 365-370 (1993).
44. Novak M: Truncated tau protein as a new marker for Alzheimer's disease. Acta Virol. 38, 173-189 (1994).
45. Rohn TT, Head E, Nesse WH, Cotman CW, Cribbs DH: Activation of caspase-8 in the Alzheimer's disease brain. Neurobiol. Dis. 8, 1006-1016 (2001).
46. Rohn TT, Head E, Su JH et al.: Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am. J. Pathol. 158, 189-198 (2001).
47. Matsui T, Ramasamy K, Ingelsson M et al.: Coordinated expression of caspase 8, 3 and 7 mRNA in temporal cortex of Alzheimer disease: relationship to formic acid extractable αβ42 levels. J. Neuropathol. Exp. Neurol. 65, 508-515 (2006).
48. Zhu X, Raina AK, Perry G, Smith MA: Apoptosis in Alzheimer disease: a mathematical improbability. Curr. Alzheimer Res. 3, 393-396 (2006).
49. Basurto-Islas G, Luna-Munoz J, Guillozet-Bongaarts AL, Binder LI, Mena R, Garcia-Sierra F: Accumulation of aspartic acid421-and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. J. Neuropathol. Exp. Neurol. 67, 470-483 (2008).
50. Fasulo L, Ugolini G, Visintin M et al.: The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis. J. Neurochem. 75, 624-633 (2000).
51. Cho JH, Johnson GV: Glycogen synthase kinase 3 β induces caspase-cleaved tau aggregation in situ. J. Biol. Chem. 279, 54716-54723 (2004).
52. Chung CW, Song YH, Kim IK et al.: Proapoptotic effects of tau cleavage product generated by caspase-3. Neurobiol. Dis. 8, 162-172 (2001).
53. Chun W, Johnson GV: Activation of glycogen synthase kinase 3β promotes the intermolecular association of tau. The use of fluorescence resonance energy transfer microscopy. J. Biol. Chem. 282, 23410-23417 (2007).
54. Hrnkova M, Zilka N, Minichova Z, Koson P, Novak M: Neurodegeneration caused by expres- sion of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats. Brain Res. 1130, 206-213 (2007).
55. Cente M, Filipcik P, Pevalova M, Novak M: Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy. Eur. J. Neurosci. 24, 1085-1090 (2006).
56. Koson P, Zilka N, Kovac A et al.: Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load. Eur. J. Neurosci. 28, 239-246 (2008).
57. Gamblin TC, Berry RW, Binder LI: Modeling tau polymerization in vitro: a review and synthesis. Biochemistry 42, 15009-15017 (2003).
58. Delobel P, Lavenir I, Fraser G et al.: Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am. J. Pathol. 172, 123-131 (2008).
59. Papasozomenos SC, Binder LI: Phosphorylation determines two distinct species of tau in the central nervous system. Cell Motil. Cytoskeleton 8, 210-226 (1987).
60. Lang E, Szendrei GI, Lee VM, Otvos L Jr: Immunological and conformation characterization of a phosphorylated immunodominant epitope on the paired helical filaments found in Alzheimer's disease. Biochem. Biophys. Res. Commun. 187, 783-790 (1992).
61. Watanabe A, Takio K, Ihara Y: Deamidation and isoaspartate formation in smeared tau in paired helical filaments. Unusual properties of the microtubule-binding domain of tau. J. Biol. Chem. 274, 7368-7378 (1999).
62. Wolozin BL, Pruchnicki A, Dickson DW, Davies P: A neuronal antigen in the brains of Alzheimer patients. Science 232, 648-650 (1986).
63. Mondragon-Rodriguez S, Mena R, Binder LI, Smith MA, Perry G, Garcia-Sierra F: Conformational changes and cleavage of tau in Pick bodies parallel the early processing of tau found in Alzheimer pathology. Neuropathol. Appl. Neurobiol. 34, 62-75 (2008).
64. Wang JZ, Gong CX, Zaidi T, Grundke-Iqbal I, Iqbal K: Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. J. Biol. Chem. 270, 4854-4860 (1995).
65. Wang JZ, Grundke-Iqbal I, Iqbal K: Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase-2A, -2B and -1. Brain Res. Mol. Brain Res. 38, 200-208 (1996).
66. Chiba Y, Shimada A, Kumagai N et al.: The senescence-accelerated mouse (SAM): a higher oxidative stress and age-dependent degenerative diseases model. Neurochem. Res. DOI: 10.1007/s11064-008-9812-8 (2008).
67. Gonsette RE: Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J. Neurol. Sci. 274, 48-53 (2008).
68. Greilberger J, Koidl C, Greilberger M et al.: Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic. Res. 42, 633-638 (2008).
69. Nunomura A, Moreira PI, Lee HG et al.: Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol. Disord. Drug Targets 6, 411-423 (2007).
70. Pope S, Land JM, Heales SJ: Oxidative stress and mitochondrial dysfunction in neurodegeneration; cardiolipin a critical target? Biochim. Biophys. Acta 1777, 794-799 (2008).
71. Moreira PI, Honda K, Liu Q et al.: Oxidative stress: the old enemy in Alzheimer's disease pathophysiology. Curr. Alzheimer Res. 2, 403-408 (2005).
72. Liu Q, Smith MA, Avila J et al.: Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic. Biol. Med. 38, 746-754 (2005).
73. Yao TM, Tomoo K, Ishida T, Hasegawa H, Sasaki M, Taniguchi T: Aggregation analysis of the microtubule binding domain in tau protein by spectroscopic methods. J. Biochem. 134, 91-99 (2003).
74. Bielska AA, Zondlo NJ: Hyperphosphorylation of tau induces local polyproline II helix. Biochemistry 45, 5527-5537 (2006).
75. Hyman BT, Augustinack JC, Ingelsson M: Transcriptional and conformational changes of the tau molecule in Alzheimer's disease. Biochim. Biophys. Acta 1739, 150-157 (2005).
76. Yin H, Kuret J: C-terminal truncation modulates both nucleation and extension phases of tau fibrillization. FEBS Lett. 580, 211-215 (2006).
77. Notari S, Strammiello R, Capellari S et al.: Characterization of truncated forms of abnormal prion protein in Creutzfeldt-Jakob disease. J. Biol. Chem. 283(45), 30557-30565 (2008).
78. Garcia-Sierra F, Wischik CM, Harrington CR, Luna-Munoz J, Mena R: Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer's disease. J. Chem. Neuroanat. 22, 65-77 (2001).
79. Park SY, Tournell C, Sinjoanu RC, Ferreira A: Caspase-3- and calpain-mediated tau cleavage are differentially prevented by estrogen and testosterone in β-amyloid-treated hippocampal neurons. Neuroscience 144, 119-127 (2007).
80. Rohn TT, Vyas V, Hernandez-Estrada T, Nichol KE, Christie LA, Head E: Lack of pathology in a triple transgenic mouse model of Alzheimer's disease after overexpression of the anti-apoptotic protein Bcl-2. J. Neurosci. 28, 3051-3059 (2008).
81. Abraha A, Ghoshal N, Gamblin TC et al.: C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J. Cell Sci. 113 (Pt21), 3737-3745 (2000).
82. Berry RW, Abraha A, Lagalwar S et al.: Inhibition of tau polymerization by its carboxy-terminal caspase cleavage fragment. Biochemistry 42, 8325-8331 (2003).
83. Gamblin TC, Berry RW, Binder LI: Tau polymerization: role of the amino terminus. Biochemistry 42, 2252-2257(2003).
84. Fasulo L, Ovecka M, Kabat J, Bradbury A, Novak M, Cattaneo A: Overexpression of Alzheimer's PHF core tau fragments: implications for the tau truncation hypothesis. Alzheimers Res. 2, 195-200 (1996).
85. Fasulo L, Ugolini G, Cattaneo A: Apoptotic effect of caspase-3 cleaved tau in hippocampal neurons and its potentiation by tau FTDP-mutation N279K. J. Alzheimers Dis. 7, 3-13 (2005).
86. Zilka N, Filipcik P, Koson P et al.: Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett. 580, 3582-3588 (2006).
87. Vega IE, Cui L, Propst JA, Hutton ML, Lee G, Yen SH: Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates. Brain Res. Mol. Brain Res. 138, 135-144 (2005).
88. Pevalova M, Filipcik P, Novak M, Avila J, Iqbal K: Post-translational modifications of tau protein. Bratisl. Lek. Listy 107, 346-353 (2006).
89. Thakur A, Wang X, Siedlak SL, Perry G, Smith MA, Zhu X: c-Jun phosphorylation in Alzheimer disease. J. Neurosci. Res. 85, 1668-1673 (2007).
90. Li HL, Wang HH, Liu SJ et al.: Phosphorylation of tau antagonizes apoptosis by stabilizing β-catenin, a mechanism involved in Alzheimer's neurodegeneration. Proc. Natl Acad. Sci. USA 104, 3591-3596 (2007).
91. Alonso AD, Zaidi T, Novak M, Barra HS, Grundke-Iqbal I, Iqbal K: Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J. Biol. Chem. 276, 37967-37973 (2001).
92. Alonso Adel C, Li B, Grundke-Iqbal I, Iqbal K: Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc. Natl Acad. Sci. USA 103, 8864-8869 (2006).
93. Stokin GB, Goldstein LS: Axonal transport and Alzheimer's disease. Annu. Rev. Biochem. 75, 607-627 (2006).
94. Stokin GB, Goldstein LS: Linking molecular motors to Alzheimer's disease. J. Physiol. Paris 99, 193-200 (2006).
95. Stokin GB, Lillo C, Falzone TL et al.: Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307, 1282-1288 (2005).
96. Smith KD, Kallhoff V, Zheng H, Pautler RG: In vivo axonal transport rates decrease in a mouse model of Alzheimer's disease. Neuroimage 35, 1401-1408 (2007).
97. Eckermann K, Mocanu MM, Khlistunova I et al.: The β-propensity of tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J. Biol. Chem. 282, 31755-31765 (2007).
98. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM: Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 156, 1051-1063 (2002).
99. Morfini G, Pigino G, Mizuno N, Kikkawa M, Brady ST: Tau binding to microtubules does not directly affect microtubule-based vesicle motility. J. Neurosci. Res. 85, 2620-2630 (2007).
100. Axonal transport hypothesis moves on to implicate presenilin: Alzheimer research forum live discussion. J. Alzheimers Dis. 6, 537-545 (2004).
101. Terwel D, Dewachter I, Van Leuven F: Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease. Neuromolecular Med. 2, 151-165 (2002).
102. Dai J, Buijs RM, Kamphorst W, Swaab DF: Impaired axonal transport of cortical neurons in Alzheimer's disease is associated with neuropathological changes. Brain Res. 948, 138-144 (2002).
103. Cuchillo-Ibanez I, Seereeram A, Byers HL et al.: Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J. 22, 3186-3195 (2008).
104. Chen HF: Aggregation mechanism investigation of the GIFQINS cross-β amyloid fibril. Comput. Biol. Chem. (2008).
105. Brody DL, Magnoni S, Schwetye KE et al.: Amyloid-β dynamics correlate with neurological status in the injured human brain. Science 321, 1221-1224 (2008).
106. Takahashi RH, Almeida CG, Kearney PF et al.: Oligomerization of Alzheimer's β-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24, 3592-3599 (2004).
107. Perez M, Moran MA, Ferrer I, Avila J, Gomez-Ramos P: Phosphorylated tau in neuritic plaques of APP(sw)/Tau (vlw) transgenic mice and Alzheimer disease. Acta Neuropathol. 116, 409-418 (2008).
108. Ding H, Johnson GV: The last tangle of tau. J. Alzheimers Dis. 14, 441-447 (2008).
109. Khlistunova I, Biernat J, Wang Y et al.: Inducible expression of tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J. Biol. Chem. 281, 1205-1214 (2006).
110. Wittmann CW, Wszolek MF, Shulman JM et al.: Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293, 711-714 (2001).
111. Yang DS, Kumar A, Stavrides P et al.: Neuronal apoptosis and autophagy cross talk in aging PS/APP mice, a model of Alzheimer's disease. Am. J. Pathol. 173, 665-681 (2008).
112. Mena R, Edwards PC, Harrington CR, Mukaetova-Ladinska EB, Wischik CM: Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. Acta Neuropathol. (Berl.) 91, 633-641 (1996).
113. Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A: Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci. Res. 54, 197-201 (2006).
114. Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K: Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl Acad. Sci. USA 98, 6923-6928 (2001).
115. Gong CX, Iqbal K: Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr. Med. Chem. 15, 2321-2328 (2008).
116. Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K: Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl Acad. Sci. USA 91, 5562-5566 (1994).
117. Alonso AC, Grundke-Iqbal I, Iqbal K: Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med. 2, 783-787 (1996).
118. Iqbal K, Alonso Adel C, Grundke-Iqbal I: Cytosolic abnormally hyperphosphorylated tau but not paired helical filaments sequester normal MAPs and inhibit microtubule assembly. J. Alzheimers Dis. 14, 365-370 (2008).
119. Iqbal K, Alonso AC, Gong CX, Khatoon S, Singh TJ, Grundke-Iqbal I: Mechanism of neurofibrillary degeneration in Alzheimer's disease. Mol. Neurobiol. 9, 119-123 (1994).
120. Guillozet-Bongaarts AL, Cahill ME, Cryns VL, Reynolds MR, Berry RW, Binder LI: Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. J. Neurochem. 97, 1005-1014 (2006).
121. Lee HG, Perry G, Moreira PI et al.: Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol. Med. 11, 164-169 (2005).
122. Aisen PS, Gauthier S, Vellas B et al.: Alzhemed: a potential treatment for Alzheimer's disease. Curr. Alzheimer Res. 4, 473-478 (2007).
123. Santa-Maria I, Hernandez F, Del Rio J, Moreno FJ, Avila J: Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Mol. Neurodegener. 2, 17 (2007).
124. Moreira PI, Zhu X, Nunomura A, Smith MA, Perry G: Therapeutic options in Alzheimer's disease. Expert Rev. Neurother. 6, 897-910 (2006).
125. Small DH: Neural network dysfunction in Alzheimer's disease: a drug development perspective. Drug News Perspect. 20, 557-563 (2007).